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Summary: We measured the activity of angiotensin converting enzyme (EC 3.4.15.1) in urine samples from normal
subjects and patients with nephrotic syndrome and chronic glomerulonephritis. Urinary excretion of angiotensin
converting enzyme in patients with nephrotic syndrome (1.58 ± 0.50 (SD) units/day; n = 15) and chronic glomerulo-
nephritis (1.01 ± 0.45 units/day; n = 12) was significantly increased compared with normal subjects (0.38 ± 0.10
units/day; n = 18). It was demonstrated that a high molecular weight form of the enzyme (more than 400000) was
mainly excreted in urines from patients with nephrotic syndrome. After trypsin treatment, this form was altered to
a low molecular weight form (290000). These two different forms of urinary angiotensin converting enzyme were
compared with the enzyme purified from human kidney, and found to be identical with respect to Km value
(2 mmol/l)5 pH Optimum (pH 8.3), Chloride ion dependency (0.8 mol/1), inhibitory effect of captopril (I50,
21 nmol/1), and behaviour tpwärds antiserum to human kidney angiotensin converting enzyme.
Erhöhte Ausscheidung von Angiotensin Converting Enzyme im Harn bei Patienten mit Nierenerkrankungen
Zusammenfassung: Bei Patienten mit nephrotischem Syndrom und chronischer Glomerulonephritis sowie bei Gesun-
den wurde Angiotensin Converting Enzyme (EC 3.4.15.1) im Harn bestimmt. Die Ausscheidung des Enzyms
(x ± s) war bei nephrotischem Syndrom (1,58 ± 0,50 U/d; n - 15) und Glomerulonephritis (l ,01 ± 0,45 U/d;
n = 12) im Vergleich zu Gesunden (0,38 ±0,10 U/d; n - 18) signifikant erhöht. Im Harn von Patienten mit nephroti-
schem Syndrom wurde hauptsächlich die Form des Enzyms mit hohem Molekulargewicht ( > 400000) ausgeschie-
den. Einwirkung von Trypsin veränderte das Enzym zu einer Form mit geringem Molekulargewicht (MT = 290000).
Beide Formen wurden mit dem aus menschlichen Nieren gereinigten Enzym verglichen. Sie waren hinsichtlich
#m-Wert (2 mrnol/l), pH-Optimum (pH 8,3), Chlorid-Abhängigkeit (0,8 mol/1), Hemmwirkung von Captopril
(I5p =21 nmol/1) und Verhalten gegen Antiserum gegen das Enzym aus Niere identisch.
Introductipn
Angiotensin converting enzyme (EC 3.4.15.1) converts
angiotensin I to angiotensin II by releasing the C-termi-
nal dipeptide (1). It also inactivates brädykinin and is
identical with kininase II (2, 3). Ward et al. (4) and
Caldwell et al. (5) have reported that the brush border
membrane of renal proximal tubules contains a high
" concentration of angiotensin converting enzyme. We
have reported that angiotensin converting enzyme is
excreted in normal human urine and that urinary excre-
tion of the enzyme is related to sodium excretion (6).
In this study, we measured the activity of urinary angio-
tensin converting enzyme in patients with nephrotic
syndrome and chronic glomerulonephritis and found
that they excreted significantly higher angiotensin
converting enzyme than normal subjects. The character
of the enzyme excreted in urine under pathological
conditions was studied.
Materials and Methods
Materials
Hippuryl-£-histidyl-Z,-leucine (hippuryl-His-Leu) was purchased
from Protein Research Foundation, Minoh, Osaka, Japan. The
molecular weight marker kit was from Boehringer Mannheim
GmbH, West Germany. Sephadex G-200 was from Pharmacia
Fine Chemicals AB, Uppsala, Sweden. Trypsin (11000 -
benzoyi-L-arginine ethyl ester (BAEE) units/mg protein) was
from Sigma Chemical Co., St. Louis, MO., U.S.A. Captopril
(INN) was kindly supplied from Sankyo Co., Ltd., Tokyo, Ja-
pan.
Probands
Normal subjects and patients with renal diseases: 18 normal
subjects (male, n - 10; female, n = 8; mean age, 45 ± 16a (SD))
were medical staffs and volunteers. Sodium was not restricted.
Patients with nephrotic syndrome and chronic glomerulonc-
phritis admittcd in our clinic were placed on a diet containing
5.8-7 g sodium Chloride per day and received no drugs during
the examination.
15 nephrotic patients (male, n = 10; female, n = 5; mcan age,
36 ± 19a) were diagnosed according to the follo\ving criteria;
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morc than 3.5 g of daily proteinuria, hypoalbuminaemia Qess
than 3 g/dl), hyperlipidacmia (total cholesterol, more than
350 mg/dl) and oedema. The mean urea nitrogen and creatinine
concentrations in serum were 19.6 ± 9.8 (SD) mg/dl (12-44 mg/
dl) and 1.37 ± 0.90 mg/dl (0.7-4.4 mg/dl), respectively. In 15
nephrotic patients, 7 patients had a renal biopsy which revealed
histopathological features (minimal change, n = 3; membranous
nephropathy, n = 3; membranoproliferative glomerulonephritis,
n = l ) .
12 patients \vith chronic glomerulonephritis (male, n = 6; female,
n = 6; mean age, 35 ± 14a) were diagnosed according to the
following criteria; persistent proteinuria (more than l year),
casts, especially erythrocyte casts, microscopic haematuria,
exclusion of Collagen diseases, diabetic and gouty nephropathy,
essential hypertension, pyelonephritis, orthostatic proteinuria
and toxic nephropathy. The mean serum urea nitrogen and
creatinine concentrations were 27.9 ± 22.3 mg/dl (12-75 mg/dl)
and 2.38 ± 2,18 mg/dl (0.7-6.2 mg/dl), respectively. 5 of 12
patients had a renal biopsy which confirmed the histological
diagnosis (membranous nephropathy, n = 4; membranoprolifera-
tive glomerulonephritis, n = 1).
Urine samples
24 h urines were collected at 4 °C. Urine samples (50 ml) were
adjusted to pH 7.0 with l mol/1 NaOH. The sample was centri-
fuged at 3000 min~\ for 20 min at 4 °C. The supematant was
fractionated \vith 3.14 mol/1 ammonium sulfate. The precipitate
was dissoived in 8 ml and dialysed against 10 mmol/1 phosphate
buffer, pH 7.8. The approximately 5-fold concentrated sample
was again centrifuged at 8000 min"1 at 4 °C and the supematant
was used for the determination of the enzymic activity. During
the preparation of the enzyme material, the recovery of enzymic
activity was approximately 70%.
Assay of angiotensin converting enzyme activity
Angiotensin converting enzyme activity was measured by the
modified method of Cushman & Cheung (7). The total l ml
assay mixture contained 80 mmol/1 borate-sodium carbonate
buffer, pH 7.8, 2 mmol/1 hippuryl-His-Leu and 0.2 ml con-
centrated urine sample. The assay mixture was incubated at
37 °C for 120 min and the reaction was stopped by adding
0.5 ml of l mol/1 HC1. The hippuric acid was extracted with
3 ml of ethyl acetate by vortex mixing for 20 s. Two ml of the
extract was evaporated and dried, and then 2 ml of distilled
water was added. The concentration of hippuric acid was deter-
mined by measuring the absorbance at 228 nm against a zero
time blank prepared by adding 0.5 ml of l mol/1 HQ to the
assay mixture before the reaction. One unit of the enzymic
activity was defined s that amount of the enzyme which
hydrolysed l μπιοΐ/πήη of hippuryl-His-Leu at 37 °C under the
described condition.
Gel filtration
Gel Filtration of a column of Sephadex G-200 (2.6 X 90 cm) for
the determination of the apparent molecular weight was carried
out by the method described previo sly (8).
Other procedures
The concentration of sodium in the urine sample was measured
by a flame photometer (Beckman, Klina Flame). Protein was
measured by the method of Lowry et al. (9). Anti-human kidney
angiotensin converting enzyme antiserum used in this study was
described previo sly (10). 5 μΐ of the antiserum inhibited half
the catalytic activity of l μδ of pure enzyme protein (0.1 U).
Statistical evaluation
Mean values were expressed s the mean ± SD. Student'* t test
M/OC UOCksl fs\r f»+n+«<»+«s««t1 ,~.»1.. . .<.:
Results
Urinary angiotensin converting enzyme activity
Urinary angiotensin converting enzyme activities in
normal subjects (n = 18) and patients with nephrotic
syndrome (n = 15) and chronic glomerulonephritis
(n = 12) were 0.38 ±0.10, 1.58±0.50and 1.01 ±0.45
units/day (x ± s), respectively (fig. 1). Uririary angio-
tensin cpnverting enzyme activities were signific ntly
higher in patients with nephrotic syndrome (p < 0.001)
and chronic glomerulonephritis (p < 0.005) than that
of normal subjects. There was no relati riship between
the enzymic activity and the concentration of sodium
excretion in patients with nephrotic syndrome (r = 0.13,
p > 0.2) and chronic glomerulonephritis (r = - 0.38,
0.2 >p> 0.1). Furthermore, there was no signiflcant
correlation between angiotensin converting enzyme
activity and protein amourit excreted in the urine
(r = 0.36, p > 0.1).
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Fig. 1. Angiotensin converting enzyme activities in urine samples
from normal subjects (n ^  18) and patients with nephro-
tic syndrome (n = 15) and chronic glomerulonephritis
(n = 12). 200 μΐ of the urine samples fractionated with
3.14 mol/1 ammonium sulfate was assayedi with 2 rnmol/1
hippuryl-His-Leu s Substrate. The enzymic actjvity was
expressed s units/day. Bars indicate the mean ± SD.
*p<0.005; **p<0.001
Multiple forms of angiotensin converting enzyme
in human urine
Fresh urine samples (150 ml) from 5 normal subjects
and 4 nephrotic patients were dialysed against 10 mmol/1
phosphate buffer, pH 7,8 at 4 °C ovenught. Each
sample (3-4 ml) concentrated with Arhicon PM 10
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membrane was applied to a column of Sephadex
G-200 (2.6 X 90 cm). Fractions of 3.25 ml were
collected. Typical profiles from normal subjects and
patients with nephrotic syndrome are shown in figure 2.
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Fig. 2. Sephadex G-200 column chromatography of human
urine. Applied samples; concentrated urine samples with
Amicon PM 10 filter. The arrow indicates the void volume
deterniined with Blue Dextran 2000. Fraction volume
3.25 ml.
•—o Enzymic activity in the urine from one normal
subject.
o—o Enzymic activity in the urine from one nephrotic
patient.
The enzymic activities appeared in fractions of
No. 42-48 (high molecular weight) and No. 52-63
(low molecular weight). The ratios of the enzymic
activity of high molfecular weight form (MT > 400000)
against that of low molecular weight form (Λ/Γ = 290000)
in 5 normal subjects and 4 nephrotic patients were
1.5 ± 0.45 and 3.8 ± 1.4, respectively.
After trypsin treatment (l mg trypsin/10 ing of protein
in the enzyme material) for 2 h at 37 °C, only the low
molecular weight form appeared in gel filtration on
Sephadex G-200 (Fig. 3).
Properties oflow molecular weight and high molecular
weight forms of urinary angiotensin converting enzyme
Low molecular weight and high molecular weight fprms
Of urinary angiotensin converting enzyme from normal
subjects were partially purified by DEAE-cellulose
column chromatography and Sephadex G-200 gel filtra-
tion and used s a sample for the following experiments.
pH optimum: The pH dependence of hydrolysis of
hippuryl-His-Leu in 80 mmol/1 borate^sodium carbonate
buffer, between pH 6 and 9 with low molecular weight
and high molecular weight forms of urinary angiotensin
converting enzyme, showed a maximum around pH 8.3,
which corresponded with that of the pure human kidney
angiotensin converting enzyme (10).
Km value: Km values oflow molecular weight and high
molecular weight forms of angiotensin converting enzyme
were determined from the Lineweaver-Burk plot at
7 different Substrate concentrations in 80 mmol/1
borate-sqdium carbonate buffer, pH 8.3. Km values of
low molecular weight and high molecular weight forms
of angiotensin converting enzyme were 2.0 mmol/1 and
identical with that of angiotensin converting enzyme
purified from human kidney.
Chloride ion dependency: The reactions of low molec-
ular weight and high molecular weight forms of angio-
tensin converting enzyme were carried out in the
presence of various concentrations of NaCl (0.1 —
l .2 mol/1). The highest activity in both forms of angio-
tensin converting enzyme was observed at the concentra-
tion of 0.8 mol/1 NaCl. The purified human kidney
angiotensin converting enzyme showed the same result.
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Fig. 3. Sephadex G-200 column chromatography of human
urine sample with or without trypsin treatment. Applied
samples: trypsin-treated sample and non-treated sample.
The arrow indicates the void volume determined with
Blue Dextran 2000. Fraction volume 3.25 ml.
•—· Enzymic activity in non-treated urine sample,
o—o Enzymic activity in trypsin-treated urine sample.
Effects of captopril and rabbit antiserum to human
kidney angiotensin converting enzyme: Both enzymic
activities oflow molecular weight and high molecular
weight forms were inhibited completely by l μπιοΐ/ΐ
captopril. I50 of captopril was identical for low and
high molecular weight forms of urinary angiotensin
converting enzyme (21 nmol/1). Low molecular weight
and high molecular weight forms of urinary angiotensin
converting enzyme were incubated with varying amounts
of anti-human kidney angiotensin converting enzyme
antiserum in 80 mmol/I borate-sodium carbonate buffer,
pH 7.8 at 37 °C for 30 min and the remaining enzymic
activities of both forms of angiotensin converting
enzyme (each 0.1 unit) were inhibited similarly. Five
μΐ of the antiserum inhibited about 50% of the activities
oflow and high molecular weight forms of urinary
angiotensin converting enzyme.
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Discussion
Recently Baggio et al. (l 1) reported that urinary angio-
tensin converting enzyme was significantly increased in
patients affected by upper urinary tract infection and
neplirolithiasis. Partially purified urinary angiotensin
converting enzyme showed the highest activity at a
NaCl concentration of 0.8 mol/1, but we measured the
activity in urine samples in 0.3 mol/1 NaCl to avoid the
interference of turbidity sometimes seen at 0.8 mol/1
NaCl. We demonstrated that angiotensin converting
enzyme activity in urine was significantly higher in
patients with nephrotic syndrome and chronic glomeru-
lonephritis than in normal subjects. However, there was
no significant relationship between urinary angiotensin
converting enzyme activity and the amount of protein
excreted in the urine. In nephrotic patients, an increase
in urinary angiotensin converting enzyme activity was
due mainly to an increased release of the high molecular
weight form of angiotensin converting enzyme. This
high molecular weight form of angiotensin converting
enzyme cannottie detected in serum (12). The high
molecular weight form of urinary angiotensin con-
verting enzyme changed to the low molecular form
when treated with trypsin. The molecular weight of the
low molecular weight form of the enzyme was the same
äs those of human serum angiotensin converting enzyme
(12) and angiotensin converting enzymes from human
kidney (10) and human lung (13), both of which were
solubilized from membrane fractions with trypsin. Prop-
erties of both low and high molecular weight forms of
urinary angiotensin converting enzyme were identicäl
with those of the enzyme purified from human kidney
with respect to pH Optimum, Km value, Chloride ion
dependency and Inhibition by captopril or antiserum to
human kidney angiotensin converting enzyme.
Various enzymes are present in urine äs a result of their
direct release from the kidney into the urine (14). In
patients with chronic glomerulonephritis with or with-
out nephrotic syndrome, membrane-bound enzymes
specific for the luminal portion öf proximal epithelia
were excreted in the urine at an increased rate (15).
Hiwada et al. (16) have reported that aminopeptidase N
(EC 3.4.11.2) in urines from nephrotic children is
significantly higher than that from normal children. The
high molecular weight form of aminopeptidase N was
identicäl with the enzyme originating from the brush
border of tubular cells. The ratio of Kij*h molecular
weight form to low molecular weight form of uriiiary
aminopeptidase N was almost unchanged in urines from
normal and nephrotic children. On the other hand, the
ratio of high mplecular weight iö low molecular weight
forms of urinary angiotensin converting enzyme was
increased in nephrotic patients compared with normal
subjects. 1t is suggested that urinary angiotensin con-
verting enzyme is released from the kidney into urine äs
a high molecular weight form and this high molecular
weight form is altered in paft tö the low molecular weight
form by trypsin-like enzyme(s) in urine. Both angio
tensin converting enzyme and aminopeptidase N are
membrane-bound enzymes. The mechanism of release of
angiotensin converting enzyme and aminopeptidase N
from the brush border of tubular cells seems to be differ-
ent.
We found a significant correlation between sodium and
angiotensin converting enzyme excretion in normal
subjects (6). In nephrotic syndrome and chronic glome-
rulonephritis, however, such a relationship between
sodium and angiotensin converting enzyme excretion
was not observed, and the high molecular weight form
of angiotensin converting enzyme was increased more
than the low molecülar weight form. This rneans that
increased urinary angiotensin converting enzyme excre-
tion under pathologic conditions mainly depends pn the
damage of proximal tübular cells äs suggested by Scher-
berich & Mondorf (15), resultirig ih'the loss of correla-
tion between sodium and angiotensin converting enzyme
excretion obserVed in normal subjects.
Acknowledgement
This work was supported in part by a Grant-in-Aid. for Encourage-
ment of Yourig Scientist (No. 477 327) from the Mihistry of
Education, Science and Culture of Japan.
References
1. Skeggs, L. T., Kahn, J. R. & Shumway, N. P. (1956) J. Exp.
Med. 103, 295-299.
2. Soffer, R. L. (1976) Ann. Rev. Biochem. 45, 73-94.
3. Nishimura, K., Yoshida, N., Hiwada, K., Ueda, E. & Kokubu,
T. (1977) Biochim. Biophys. Acta4S3, 398-408.
4. Ward, P. E., Gedney, C. D., Dowben, R. M. & Erdös, E. G.
(1975) Biochem. J. 151, 755-758.
5. Caldwell, P. R. B., Seegal, B. C., Hsu, K. C, Das, M. & Soffer,
R. L. (1976) Science 191, 1050-1051.
6. Kokubu, T., Kato, I., Nishimura, K., Hiwada, K. & Ueda, E.
(1978) Clin. Chim. Acta 89, 375-379.
7. Cushman, D. W. & Cheung, H. S. (1971) Biochem. Pharma-
col. 20, 1637-1648.
8. Hiwada, K., Ito, T., Yokoyama, M. & Kokubu, T. (1980)
Eur. J. Biochem. 104, 155-165.
9. Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R.
J. (1951) J. Biol. Chem. 193, 265-275.
J. Clin. Chem. Clin. Biochem. / Vol. 20, 1982 / No. 7
10. Takada, Y., Hiwada, K. & Kokubu,-T. (1981) J. Biochem.
(Tokyo) 90,1309-1319.
11. Baggio, B., Favarp, S., Cantaroi S., Bertazzo, L., Fruriziö,
A. & Borsatti, A. (1981) Clin. Chim. Acta 709, 211-218.
12. Ueda, E., Nishimura, K., Kato, L, Hayashi, Y., Kokubu, T.,
Yoshida, N. & Tachibana, t. (1978) Jap. J. Thorac. Dis. 16,
94-97.
13. Nishimura, K„ Yoshida, N., Hiwada, K., Ueda, E. & Kokubu,
T. (1978) Biochim. Biophys. Acta 522, 229-237.
14. Räab, W. P. (1972) Clin. Chem. 18, 5-25.
15. Scherberich, J. E. & Mondorf, W. A. (1979) Excretion-of
kidney brüsh border antigens äs a quantitative indicator of
tubular damage: In: Diagnostic Significance of Enzymes and
Proteins in Urine (Dubach, U. C. & Schmidt, U, eds.), Hans
Hubex Publishes, Bern, Stuttgart and Vienna.
16. Hiwada, K., Yamaguchi, C., Inaoka, Y.Ä Kokubu, T.
(1976) Clin. Chim. Acta 75, 31-39. » ?
Prof. Tatsuo Kokubu, M. D.
2nd Department of Internal Medicine,
Ehime Üniversity School of Medicine,
Onsen-gun, Ehime 791-02,( Japan
